Serum Chordecone Concentration in Guadeloupean Population: Impact of a Multidisciplinary Support Program on the Reduction of the Contamination Level. (ChlorGua)

The French West Indies (Guadeloupe, Martinique) are characterized by a major use of pesticides in bananas plantation from the 1950s. These crops used organochlorine insecticides and especially chlordecone (CLD) from 1972 to 1993. The lack of biotic and abiotic degradation of CLD led to persistent soil pollution, contamination of surface and deep waters, of numerous plant and animal, and of the population. The extent and persistence of CLD contamination over time is a major issue for these territories. An internal reference value (0.4μg/l) was recently determined. Although useful for a population approach, it must be used with caution for the interpretation of an individual result. In response to the strong social demand expressed by the population for access to free chlordecone blood tests, a screening program for blood chlordecone test was authorized by the 2019 French Finance Act.

Study Overview

• Status: Recruiting
• Conditions: Chlordecone Level
• Intervention / Treatment: Other: CHLORGUA

Detailed Description

The target populations will receive an invitation letter with an information notice and a consent form. The referral physician will explain the program and the research project and prescribe a standardized blood sample test.

Blood samples will be taken in one of the biology laboratories participating in the project. Serum chordecone test will be performed by the Pasteur Institute of Guadeloupe. Blood samples for biological collection will be sent to the Biological Resource Center, Karubiotec™. The result of the chlordécone level will be sent back to each subject with a recommendation note based on the chlordécone level value. Phone contact information for those who consented to the study will be forwarded to the research assistant for the questionnaire.

• Study Type: Interventional
• Enrollment (Estimated): 3000
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Valérie HAMONY-SOTER; Phone Number: +590590934686; Email: valerie.soter@chu-guadeloupe.fr
• Study Contact Backup: Name: Eunice NUBRET; Email: eunice.nubret@chu-guadeloupe.fr

Study Locations

• Guadeloupe
  • Guadeloupe
    • Pointe-à-Pitre, Guadeloupe, Guadeloupe, 97159
      • Recruiting
      • Centre Hospitalier Universitaire de la Guadeloupe
      • Contact: Eunice NUBRET; Email: eunice.nubret@chu-guadeloupe.fr
      • Contact: Valérie SOTER; Phone Number: +590590934686; Email: valerie.soter@chu-guadeloupe.fr
      • Principal Investigator: Jacqueline DELOUMEAUX, Doctor

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

• All subject overs 18 years of age residing in Guadeloupe invited to participate to the program by the Regional Health Agency or subjects who requested a test from their doctor in the framework of the ministerial measure.
• Subjects who have read the information note and signed the consent to participate in the study
• Subjects with social security coverage

Exclusion Criteria:

• Refusal to participate
• Person not affiliated with a social security scheme
• Person under legal protection (safeguard of justice, guardianship, curatorship, etc.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Other: guadeloupean subject; All subject overs 18 years of age residing in Guadeloupe invited to participate to the program

Other: CHLORGUA; The target populations will receive an invitation letter with an information notice and a consent form. The referral physician will explain the program and the research project and prescribe a standardized blood sample test. Blood samples will be taken in one of the biology laboratories participating in the project. Serum chordecone test will be performed by the Pasteur Institute of Guadeloupe. Blood samples for biological collection will be sent to the Biological Resource Center, Karubiotec™. The result of the chlordécone level will be sent back to each subject with a recommendation note based on the chlordécone level value. Phone contact information for

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
chlordecone level	ug/l	between Day0 to Day15
risk factors	chlordeconemia survey	between day 15 and day 45 ,

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
chlordecone level	ug/l	At 9 months after intervention
chlordecone level	ug/l	At 18 months after intervention
chlordecone level	ug/l	at delivery for pregnant women
impact of an intervention	chlordeconemia survey	between day 15 to day 45, at month 9 and month 18

Collaborators and Investigators

• Sponsor: Centre Hospitalier Universitaire de la Guadeloupe
• Investigators: Principal Investigator: Jacqueline DELOUMEAUX, Doctor, CHU de la Guadeloupe

Study record dates

Study Major Dates

• Study Start (Actual): June 26, 2022
• Primary Completion (Estimated): June 1, 2028
• Study Completion (Estimated): June 1, 2028

Study Registration Dates

• First Submitted: November 14, 2025
• First Submitted That Met QC Criteria: November 18, 2025
• First Posted (Actual): November 26, 2025

Study Record Updates

• Last Update Posted (Actual): November 26, 2025
• Last Update Submitted That Met QC Criteria: November 18, 2025
• Last Verified: October 1, 2025

More Information

Terms related to this study

• Keywords: risk factors; pesticides; chlordecone; Guadeloupe
• Other Study ID Numbers: PAP_RIPH2_2022/01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No